185 related articles for article (PubMed ID: 28385379)
41. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
42. CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy.
Fisher OM; Levert-Mignon AJ; Lehane CW; Botelho NK; Maag JL; Thomas ML; Edwards M; Lord SJ; Bobryshev YV; Whiteman DC; Lord RV
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):746-754. PubMed ID: 27577713
[TBL] [Abstract][Full Text] [Related]
43. Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.
Lynam-Lennon N; Bibby BA; Mongan AM; Marignol L; Paxton CN; Geiersbach K; Bronner MP; O'Sullivan J; Reynolds J; Maher SG
Mol Med; 2016 May; 22():388-97. PubMed ID: 27254108
[TBL] [Abstract][Full Text] [Related]
44. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
45. Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer?
Lee A; Wong AT; Schwartz D; Weiner JP; Osborn VW; Schreiber D
Ann Thorac Surg; 2016 Aug; 102(2):433-8. PubMed ID: 27154156
[TBL] [Abstract][Full Text] [Related]
46. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract][Full Text] [Related]
47. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.
Odenthal M; Hee J; Gockel I; Sisic L; Schmitz J; Stoecklein NH; Driemel C; Möhlendick B; Schmidt T; Knoefel WT; Lang H; Büttner R; Ott K; Vallböhmer D
Int J Cancer; 2015 Jul; 137(1):230-7. PubMed ID: 25429911
[TBL] [Abstract][Full Text] [Related]
48. TGM2: a cell surface marker in esophageal adenocarcinomas.
Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG
J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664
[TBL] [Abstract][Full Text] [Related]
49. Utility of
Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
[TBL] [Abstract][Full Text] [Related]
50. Molecular Marker Expression Is Highly Heterogeneous in Esophageal Adenocarcinoma and Does Not Predict a Response to Neoadjuvant Therapy.
Bronson NW; Diggs BS; Bakis G; Gatter KM; Sheppard BC; Hunter JG; Dolan JP
J Gastrointest Surg; 2015 Dec; 19(12):2105-10. PubMed ID: 26394876
[TBL] [Abstract][Full Text] [Related]
51. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.
Griffin JM; Reed CE; Denlinger CE
Ann Thorac Surg; 2012 Jun; 93(6):1855-9; discussion 1860. PubMed ID: 22516835
[TBL] [Abstract][Full Text] [Related]
52. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
[TBL] [Abstract][Full Text] [Related]
53. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
Alakus H; Bollschweiler E; Hölscher AH; Warnecke-Eberz U; Frazer KA; Harismendy O; Lowy AM; Mönig SP; Eberz PM; Maus M; Drebber U; Siffert W; Metzger R
Ann Surg Oncol; 2014 Dec; 21(13):4375-82. PubMed ID: 24986238
[TBL] [Abstract][Full Text] [Related]
54. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.
Hölscher AH; Drebber U; Schmidt H; Bollschweiler E
Ann Surg; 2014 Nov; 260(5):779-84; discussion 784-5. PubMed ID: 25379849
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
56. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
Bibby BA; Reynolds JV; Maher SG
PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
[TBL] [Abstract][Full Text] [Related]
57. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
[TBL] [Abstract][Full Text] [Related]
58. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M
BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090
[TBL] [Abstract][Full Text] [Related]
59. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
